(VIANEWS) – IMMOBEL (IMMO.BR), MEDISTIM (MEDI.OL), EQUASENS (EQS.PA) are the highest payout ratio stocks on this list.
We have congregated information about stocks with the highest payout ratio up to now. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. IMMOBEL (IMMO.BR)
283.72% Payout Ratio
Immobel SA engages in the real estate development business in Belgium, Luxemburg, France, Germany, Poland, and Spain. The company undertakes office, residential, and retail projects, as well as develops real estate projects for living, working, and recreational activities. It also provides project management and leasing services. The company was formerly known as Allfin NV and changed its name to Immobel SA in June 2016. The company was incorporated in 1863 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, IMMOBEL has a trailing twelve months EPS of €1.07.
PE Ratio
IMMOBEL has a trailing twelve months price to earnings ratio of 32.34. Meaning, the purchaser of the share is investing €32.34 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.79%.
Moving Average
IMMOBEL’s worth is below its 50-day moving average of €36.37 and way below its 200-day moving average of €44.43.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 24, 2023, the estimated forward annual dividend rate is 3.05 and the estimated forward annual dividend yield is 8.68%.
Volume
Today’s last reported volume for IMMOBEL is 671 which is 80.28% below its average volume of 3403.
More news about IMMOBEL.
2. MEDISTIM (MEDI.OL)
59.15% Payout Ratio
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.31.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 38.35. Meaning, the purchaser of the share is investing kr38.35 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 1.8%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.3%, now sitting on 499.39M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MEDISTIM’s EBITDA is 114.4.
More news about MEDISTIM.
3. EQUASENS (EQS.PA)
34.45% Payout Ratio
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.05.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 25.54. Meaning, the purchaser of the share is investing €25.54 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.59%.
Volume
Today’s last reported volume for EQUASENS is 760 which is 79.75% below its average volume of 3754.
More news about EQUASENS.
4. HEINEKEN (HEIA.AS)
31.4% Payout Ratio
Heineken N.V. brews and sells beer and cider in Europe, Americas, Africa, the Middle East, Eastern Europe, and the Asia Pacific. The company also provides soft drinks and water. It offers its beers under the Heineken, Amstel, Sol, Tiger, Birra Moretti, Pure Piraña, Desperados, Edelweiss, and Lagunitas brands; and cider under the Strongbow Apple Ciders, Orchard Thieves, Cidrerie Stassen, Bulmers, and Old Mout brands, as well as under regional and local brands. The company offers its products to retailers, wholesalers, cafes, bars, pubs, hotels, and restaurants. Heineken N.V. was founded in 1864 and is headquartered in Amsterdam, the Netherlands. Heineken N.V. operates as a subsidiary of Heineken Holding N.V.
Earnings Per Share
As for profitability, HEINEKEN has a trailing twelve months EPS of €4.65.
PE Ratio
HEINEKEN has a trailing twelve months price to earnings ratio of 19.41. Meaning, the purchaser of the share is investing €19.41 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.6%.
Moving Average
HEINEKEN’s value is below its 50-day moving average of €95.91 and below its 200-day moving average of €94.22.
More news about HEINEKEN.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1%, now sitting on 1 for the twelve trailing months.
Sales Growth
1’s sales growth is 1% for the current quarter and 1% for the next.
More news about 1.
